Longevity Research
Aging claims tested against human outcomes, source quality, and the difference between endogenous biology and treatment evidence.
ASK BETTER QUESTIONS
What changes a longevity research evidence decision?
- Are there patient-important human outcomes?
- Is the evidence limited to cells, animals, or biomarkers?
- Has a narrow rare-disease result been generalized?
EVIDENCE RECORDS
Longevity Research evidence records.
Epitalon
Epitalon's longevity narrative is much stronger than its verifiable modern human evidence. The record remains hypothesis-generating, not outcome-proving.
Open evidence recordMOTS-c
MOTS-c is biologically interesting, but human physiology observations are frequently mistaken for evidence that an exogenous product improves health or performance.
Open evidence recordSS-31 / Elamipretide
SS-31 is no longer simply an unapproved research peptide: elamipretide now has one narrow accelerated-approval pathway, with confirmatory evidence still required.
Open evidence recordGlutathione
Glutathione evidence is inseparable from route, formulation, outcome, and product quality. Oral biomarker studies do not establish intravenous efficacy or safety.
Open evidence recordDIRECT COMPARISONS